华夏英泰作为国内兼具国际水平原创科研实力、中国速度的高效产品转化能力 的创新型细胞疗法“硬科技”企业，于2018年由全球知名免疫学家林欣教授领衔创 立，基于创始人林欣教授在清华大学和国家实验室原创转化的STAR-T和通用型定点 整合技术两大平台，针对当前免疫细胞治疗难点，开发革命性的患者可及的T细胞药 物。公司搭建了较为成熟的早期研发、工艺开发和质量研究、临床开发团队；已开 展的几十例血液瘤和实体瘤临床实验，取得了良好的安全性和有效性数据，并多次 在国际权威会议和学术期刊发布；特别是在自身免疫性疾病、血液瘤和实体瘤的自 体型和通用型细胞产品的研发中有行业突破进展，受到领域内一线研究者和国际同 行的高度认可。公司现已获得2个中国IND临床批件和1个FDA孤儿药认定；公司首个 产品有望在2027年递交NDA上市申请。

 At present, BristarImmunotech focuses on the development of new targets for  hematoma, solid tumor, and universal cell therapy products. The company has carried  out dozens of clinical trials of hematoma and solid tumor, and achieved good safety  and effectiveness data, especially in solid tumor, acute myeloid leukemia and universal  cell therapy for serious autoimmune diseases such as systemic lupus erythematosus industry breakthrough progress; The company has now obtained 2 Chinese IND clinical  approval documents and 1 FDA orphan drug identification, is actively promoting the  clinical progress of products, hope that the innovation results can benefit the majority  of patients as soon as possible!

地址：北京市昌平区生命科学园医科路9号院4号楼五层

Building 4, Medical and Pharma Tech Center, Life Science

Park, Changping District, Beijing, 102206 China

电话：010-60608019